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Abstract 
 
This study aimed to determine the therapeutic benefit of a nanoparticular formulation for 
the delivery of inducible nitric oxide synthase (iNOS) gene therapy in a model of breast 
cancer metastasis. Nanoparticles comprising a cationic peptide vector, RALA, and 
plasmid DNA were formulated and characterized using a range of physiochemical 
analyses. Nanoparticles complexed using iNOS plasmids and RALA approximated 60 
nm in diameter, with a charge of 25 mV. A vector neutralization assay, performed to 
determine the immunogenicity of nanoparticles in immunocompetent C57BL/6 mice, 
revealed that no vector neutralization was evident. Nanoparticles harboring iNOS 
plasmids (constitutively active cytomegalovirus (CMV)-driven, or transcriptionally-
regulated human osteocalcin (hOC)-driven) evoked iNOS protein expression and nitrite 
accumulation, and impaired clonogenicity in the highly aggressive MDA-MB-231 human 
breast cancer model. Micrometastases of MDA-MB-231-luc-D3H1 were established in 
female BALB/c SCID mice by intracardiac delivery. Nanoparticulate RALA/CMV-iNOS 
or RALA/hOC-iNOS increased mean survival in mice bearing micrometastases by 27% 
compared to controls, and also provoked elevated blood nitrite levels. Additionally iNOS 
gene therapy sensitized MDA-MB-231-luc-D3H1 tumors to docetaxel treatment. Studies 
demonstrated that systemically delivered RALA-iNOS nanoparticles has therapeutic 
potential for the treatment of metastatic breast cancer. Furthermore, detection of nitrite 
levels in the blood serves as a reliable biomarker of treatment.   
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3 
Introduction 
 
An obstacle to genetic therapies is the absence of a vector with the DNA-delivery ability 
of a virus that lacks the immunogenicity commonly associated with viral vectors. We 
have developed a cationic fusogenic peptide vector, RALA, that on exposure to anionic 
nucleic acids, self assembles into nanoscale particles suitable for cell membrane 
penetration. Endosomal escape, consequent of conformational change at low pH ensures 
that the genetic cargo can reach the nucleus and achieve transgene expression. 1 We 
previously demonstrated the remedial potential of RALA-delivered therapeutic cargoes; 
growth of ZR-75-1 breast cancer xenografts was abrogated by plasmid FK506-binding 
protein-like (FKBPL), 2 while nanocomplexation of anionic bisphosphonates with RALA 
afforded the agents cytotoxicity against PC-3 prostate cancer cells in vitro and in 
xenografts following intratumoral injection. 3 In this study, we aimed to provoke a 
therapeutic benefit in a model of aggressive breast cancer by nanocomplexation of 
plasmid inducible nitric oxide synthase (iNOS) with RALA.  
 
The paradoxical relationship between nitric oxide (·NO) and transformed tissue, whereby 
low concentrations of the gasotransmitter provoke an aggressive phenotype, but higher 
concentrations are detrimental to the tumor, 4 has led to a divergence in the discipline, 
with attempts being made to either promote or interfere with ·NO signaling. The 
mechanisms by which ·NO mediates its effects in neoplastic conditions are diverse, but 
can be broadly characterized into promotion (low ·NO) or inhibition (high ·NO) of 
apoptosis, promotion (low) or inhibition (high) of proliferation, and stimulation (low) or 
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attenuation (high) of angiogenesis. 4 ·NO can react with inorganic molecules (i.e. oxygen, 
superoxide or transition metals), structures in DNA, prosthetic groups or proteins, and 
can elicit beneficial or detrimental responses dependent on radical concentration and 
local environmental conditions. 5 Host macrophages that infiltrate tumors rely partially on 
the cytotoxic properties of ·NO to evoke an anti-tumoral response. 6  
 
The majority of attempts to exploit the tumoricidal properties of ·NO involve using a 
·NO donor molecule. Many such donors exist, and are broadly represented by the organic 
nitrates, metal-NO complexes, S-nitrosothiols, sydnonimines, diazeniumdiolates 
(NONOates), and ·NO-drug hybrids. 4 One ·NO-donating prodrug that has received 
particular attention is JS-K; JS-K induced apoptosis in a range of breast cancer cell lines, 
but spared normal HMEC endothelial cells and MCF-10A. 7 JS-K was recruited onto the 
National Cancer Institute’s Rapid Access to Interventional Development (RAID) 
program, accelerating its progression as a potential therapeutic. 8  
 
As an alternative approach to achieving therapeutic levels of intra-tumoral ·NO, we 9-14, 
and others 15-17 have demonstrated the benefit of iNOS as a therapeutic transgene. 
Constitutive iNOS expression abolished clonogenicity in ZR-75-1 breast cancer cells, 13 
and sensitized to cisplatin in human cancer cell lines and murine RIF-1 xenografts, 9 and 
in A549 models of human primary and metastatic lung cancer. 17 To limit ·NO release 
from an iNOS gene therapeutic to target tumors, we have deployed a transcriptional 
targeting approach using the human osteocalcin (hOC) promoter to drive iNOS 
expression. The hOC promoter is activated by transcription factors such as Runx2 and 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 5 
Fra-2, which are commonly overexpressed in cancers that metastasise to bone. 18 hOC-
iNOS-derived ·NO achieved almost complete elimination of colony forming ability in 
PC-3 and DU145 castration-resistant prostate cancer cells, as well as inducing stasis in 
PC-3 xenografts. 11,19  
 
The purpose of the current study was to determine whether cationic RALA-based 
nanoparticles carrying an iNOS transgene had a therapeutic impact in mice bearing 
MDA-MB-231 (known to be sensitive to ·NO donor DETA/NO, through generation of 
dinitrogen trioxide 20) micrometastases.  
Results 
Nanoparticle characterization 
Incubation of RALA with plasmid DNA in water resulted in the formation of 
nanoparticles with physical characteristics suitable for cellular internalization (Figure 1a)  
1,2,21. 
  
Subcellular nanoparticle localization 
Labeling with Cy3 did not impact the physicochemical properties of nanoparticles 
(Figure 1b). The ability of RALA to deliver Cy3-labeled pEGFP-1 nanoparticles to the 
nucleus of MDA-MB-231-luc-D3H1 was confirmed by confocal fluorescence 
microscopy using orthogonal sectioning (to construct XZ and YZ images to correspond to 
an area of interest in an XY image following collection of a Z-stack of images); by 60 
min following commencement of transfection, Cy3 fluorescence was evident within the 
confines of the cell, and within 120 min, was detected within the nucleus (Figure 1c).  
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Vector neutralization assay 
The transfecting potency of RALA/pEGFP-N1 in ZR-75-1 breast cancer cells was not 
detrimentally affected by incubation of the nanoparticles with pooled sera from mice that 
had received RALA/pEGFP-N1 nanoparticles (single or multiple administrations 
thereof). Repeated measures two-way ANOVA with Dunnett’s correction for multiple 
comparisons was used to compare sera from nanoparticle-treated mice with other 
treatments (Figure 2a). In no case did incubation in sera from nanoparticle-treated mice 
lessen GFP expression; rather, nanoparticles incubated in sera from nanoparticle-treated 
mice provoked slightly higher transfection ability. The degree of fluorescence of ZR-75-1 
was diminished slightly when nanoparticles were incubated in 10% serum, although this 
cannot be down to antibody neutralization, as nanoparticles incubated in sera from mice 
that received PBS, pDNA or RALA only, or those incubated in FBS also evoked less 
fluorescence when serum concentration was 10% (Figure 2b).  
 
Sera from mice that received PBS, pEGFP-N1, RALA or RALA/pEGFP-N1 
nanoparticles produced limited immunoreactivity in RALA/pEGFP-N1 nanoparticle-
coated wells of an ELISA plate (Figure 2c). There was no significant difference (P>0.05) 
in immunoreactivity between sera from mice that received nanoparticles and mice that 
received any other treatment (repeated measures two-way ANOVA with Tukey multiple 
comparisons test).  
 
iNOS transgene expression in MDA-MB-231-luc-D3H1  
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Transfection of MDA-MB-231-luc-D3H1 with CMV- or hOC-iNOS provoked 
accumulation of nitrites in culture medium as analyzed 48 h post transfection; iNOS 
protein expression was also detectable by western blot (Figure 3a).  
 
Clonogenics 
MDA-MB-231-luc-D3H1 transfected with RALA/hOC-iNOS (61.70% ± 10.39) or 
RALA/CMV-iNOS (68.40% ± 13.32) had lower clonogenicity than untransfected control 
cells. Treatment with 1 mM aminoguanidine (NOS inhibitor)  22 partially blocked this 
inhibition of clonogenicity, (79.4% ± 16.2 and 85.4% ± 15.6 of control for RALA/hOC-
iNOS and RALA/CMV-iNOS respectively) (Figure 3b). Optimization of transfection 
conditions are summarized in Supplemental Figure S1.  
 
RALA/iNOS gene therapy slows progression of metastatic breast cancer in mice 
Administration of hOC/CMV-iNOS-loaded RALA nanoparticles delayed 
bioluminescence accumulation (Figure 4a, 4d) and disease progression in mice bearing 
MDA-MB-231-luc-D3H1 micrometastases (Figure 4b). Control and vehicle only mice 
had a median post-implantation survival of 31.5 and 30.0 days respectively. Median 
survival was significantly increased (Log-rank (Mantel-Cox) test) by treatment with 
RALA/hOC-iNOS (38.5 days; P = 0.001), and RALA/CMV-iNOS therapy (40 days; P > 
0.001).  
 
Figure 4c and 4d comprises biochemical and physical data from a single mouse per 
treatment group (those individuals whose post-implantation survival was closest to the 
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relevant treatment’s median value – cumulative data of all mice are presented in 
Supplemental Figures S2 and S3). Mice that received iNOS transgenes lost mass 
(Figure 4c) and developed bioluminescent signal (Figure 4d) more slowly than control.  
 
Blood nitrite levels in both RALA/iNOS complex-receiving mice were up to nine-fold 
higher than the blood nitrite levels of control mice (Figure 4e). Opsonization and 
sequestration by the mononuclear phagocyte system is a common fate of cationic 
nanoparticles following systemic administration – this could explain why gene expression 
following treatment with RALA/pLuciferase 1 and other similarly charged gene therapy 
nanoparticles 23 is seen mainly in the lungs and liver of mice. To determine whether these 
organs were less susceptible to metastases colonization in RALA/iNOS-treated mice, we 
attempted to quantify the number of metastatic lesions in mice at endpoint, and to make 
an estimation of the location of the lesions. The number of lesions evident in the final 
images (i.e. experimental endpoint) of each mouse was counted, their location was 
assigned to one of head, thoracic, abdominal or skeletal, and the number at each location 
was counted. Mice that received iNOS gene therapy had fewer metastatic foci than 
control mice, and RALA/CMV-iNOS or RALA/hOC-iNOS treatment appeared to inhibit 
metastases development in the abdominal cavity and the head, but had no impact on 
lesion development in the skeleton or thoracic cavity (Supplemental Figure 4). The 
inhibition of lesion development in the abdomen may be due to iNOS gene 
overexpression in the liver, although we did not investigate this further. 
 
iNOS sensitizes to docetaxel in vitro and in vivo 
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Transfection of MDA-MB-231-luc-D3H1 with either RALA/CMV-iNOS or 
RALA/hOC-iNOS nanoparticle complexes before treatment with docetaxel enhanced the 
docetaxel response. Docetaxel dose-dependently inhibited the viability of MDA-MB-
231-luc-D3H1 (EC50 of 82.7 nM), while transfection with RALA/hOC-iNOS or 
RALA/CMV-iNOS reduced the EC50 to 33.3 nM and 34.9 nM respectively (both p<0.05, 
assessed by repeated measures one-way ANOVA with Geisser-Greenhouse correction; 
Figure 5a). 
 
Metastases-bearing mice that were treated with docetaxel had a median survival of 44.0 
days. Although co-administration of docetaxel with RALA/hOC-iNOS (46.0 days; P = 
0.8601) or RALA/CMV-iNOS (49 days; P = 0.3757) complexes did not significantly 
improve median survival, maximal survival (51 days in docetaxel only) was considerably 
longer in both docetaxel + RALA/hOC-iNOS and RALA/CMV-iNOS treatment groups 
(78 and 86 days respectively; Figure 5b). Figure 5c and 5d represent mass loss and 
bioluminescence accumulation in individual mice whose survival was closest to median 
survival; cumulative data on all mice is presented in Supplemental Figure S5.  As is 
evident in Figure 5d, luminescence accumulation was retarded in the gene therapy plus 
docetaxel groups until therapy was withdrawn, while in docetaxel-treated mice, 
luminescence accumulation progressed from day 5 onwards, although at a slower rate 
than in control.  
 
Discussion 
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The evidence presented here demonstrates for the first time the therapeutic utility of 
iNOS gene therapy following systemic administration. In our assays, both RALA/iNOS 
strategies impressively prolonged the survival of mice bearing MDA-MB-231 
micrometastases. Using blood nitrite measurements, we demonstrated that receiving 
either gene therapy regimen provoked ·NO generation in these mice. Assessment of 
circulating nitrite concentrations in this system was a viable biomarker for successful 
transgene expression; changes in ·NO flux have been used previously to confirm 
therapeutic ·NO generation  24, although this was by invasive insertion of an amiNO 700 
probe.  
Nanoparticles formed of RALA and either iNOS plasmid displayed size and charge 
characteristics suitable for cellular internalization. Indeed, our observations were in 
agreement with previous studies on the internalization of RALA/plasmid DNA 
nanoparticles, which occurs rapidly, and relies on both clathirin- and caveolin-dependent 
processes. 1 We have previously demonstrated that iNOS gene therapies delivered 
intratumorally produce an impressive therapeutic benefit  9-12,19, and described reporter 
gene expression when the luciferase gene was delivered systemically using RALA  1, but 
this is the first description of systemic RALA-mediated therapeutic transgene delivery, 
and the first description of systemically-delivered iNOS for cancer gene therapy. Both 
iNOS gene therapy constructs provoked inhibition of clonogenicity in vitro. ·NO exerts 
its anti-cancer benefit when its intracellular concentration is in the micromolar range  25; 
although we did not assess intracellular ·NO concentration following transfection, the 
accumulation of nitrites in culture medium is indicative of considerable increase in 
intracellular ·NO content. The fate of transfected cells likely depends on the degree of 
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·NO production, but could include apoptosis, attraction of macrophages, or toxicity due 
to a bystander effect. 26  
 
A concern associated with indiscriminate production of ·NO is the deleterious side effects 
that may manifest, such as hypotension. Numerous strategies have been employed to 
limit ·NO production to the disease site, including β-galactosidase-provoked release of 
·NO/HNO from IPA/NO, 27 or the nitroreductase-dependent release of ·NO from 1-(2-
methylpiperidin-1-yl)diazen-1-ium-1,2-diolate. 28 Likewise, RRx-001, which 
preferentially releases ·NO in the hypoxic environment, attenuated murine SCC VII 
xenograft growth and sensitized to fractionated radiotherapy, doubling the survival time 
of mice. 29 Ligand targeting of nanoparticles is a common targeting strategy, with tumor-
associated dysregulated expression of the receptors of transferrin, folic acid, epidermal 
growth factor and hyaluronic acid being particularly popular. 30 We have previously 
employed numerous transcriptional targeting strategies. Utilization of the prostate 
specific membrane antigen (PSMA) promoter elicited iNOS transgene expression in 
prostate cancer lines, but not in colon or breast carcinoma lines. 11 We have also used 
inducible promoters to control iNOS expression; the WAF1/p21 promoter, whose activity 
is induced by radiation, when used to drive iNOS expression, evoked RIF-1 and HT29 
tumor growth delay that exceeded that observed with either a fractionated radiotherapy 
strategy alone 12 or with a single X-ray dose (10 or 20 Gy). 14  
 
It was unsurprising that RALA/CMV-iNOS was more potent than RALA/hOC-iNOS, 
given the constitutive activity of the promoter, although the transcriptionally-targeted 
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therapy also significantly improved the survival of mice bearing metastases. 
Overexpression of Runx2, characteristic in MDA-MB-231 31, is responsible for activation 
of the hOC promoter 18. We have shown previously that PC3 prostate cancer cells express 
GFP and iNOS transgenes as provoked using hOC, but LNCaP prostate cancer cells do 
not  19; LNCaP are known to express Runx2 to a much lower extent than PC3 32. Given 
that Runx2 expression is elevated in metastatic bone lesions of breast cancer patients, but 
absent in corresponding primary tumors 31, employment of a Runx2-activatable therapy 
should result in maximal iNOS transgene expression in the most aggressive tumor sites, 
and spare normal tissue  33. Runx2 has also been implicated in the progression of prostate  
34, lung  35 and thyroid  36 cancers, which preferentially target the bone for metastatic 
colonization. We expect that these and other tumors that overexpress Runx2 would 
benefit from hOC-iNOS gene therapy.  
 
Despite the compelling evidence of therapeutic potential of iNOS gene therapy in 
neoplastic conditions 9,12,14-16,19,37,38, the dichotomy of the relationship between ·NO and 
the tumor environment confers skepticism when it comes to overexpressing ·NO. 
Although iNOS expression was negatively correlated with lesion grade in a cohort of 
invasive ductal breast carcinomas  39, indicating a possible role of iNOS in the prevention 
of metastasis, iNOS expression has conversely been implicated as a marker of poor 
prognosis in several malignancies, including prostate, colon and breast  40. Stratification 
of a breast cancer patient cohort by estrogen receptor (ER) expression revealed that iNOS 
expression was predictive of poorer survival in ER- patients  41, while high iNOS 
expression was similarly detrimental in a range of triple-negative breast cancer patient 
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cohorts.  42 Consequently, efforts are being made to repress iNOS activity as a therapeutic 
strategy - NOS inhibitors such as AG  22 have been investigated in pre-clinical settings, 
and more recently, ASP9853, an inhibitor of iNOS dimerization, was tested in 
combination with docetaxel in patients with advanced solid tumors 43.  
 
However, while iNOS expression may correlate with disease status in some analyses, it is 
important to note that protein levels do not necessarily correlate with activity. Several 
factors could affect the translation of iNOS mRNA to functional protein, and the 
production of ·NO. In the mouse RENCA renal cancer cell line, iNOS mRNA expression 
is not translated into functional protein, resultant of post-transcriptional modification by 
miR-146a. Treatment of RENCA cells with anti-miR-146a restores the cells’ ability to 
translate iNOS protein, with concurrent ·NO production, and xenografts of these cells had 
considerably slower growth dynamics than negative control anti-miR-treated cells. 44 
miR-146a expression may impact iNOS expression in the clinical setting, potentially 
complicating prognostication based upon iNOS mRNA expression profiling. Indeed, 
miR-146a was overexpressed in triple-negative breast cancer cell lines (including MDA-
MB-231), and was significantly overexpressed in triple-negative breast cancer patient 
samples than in non-triple-negative patients  45. Another factor that plays a role in iNOS 
activity is its co-factor tetrahydrobiopterin; NOS enzymes in cancer cells may 
preferentially produce superoxide and peroxynitrite over ·NO itself, resultant of 
inappropriate tetrahydrobiopterin:dihydrobiopterin (BH4:BH2) proportions. Restoration 
of appropriate BH4:BH2 proportions in MCF-7 and MDA-MB-231 breast cancer cells 
using sepiapterin manifested dose-dependent cytotoxicity that was diminished when NOS 
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was inhibited. Oral sepiapterin also delayed MDA-MB-231 xenograft progression. In this 
model, aberrant BH4:BH2 proportion is likely to deprive the tumor of the therapeutic 
benefit afforded by ·NO 46.  
 
We investigated the impact of iNOS overexpression on sensitivity to docetaxel. A taxane, 
docetaxel acts by preventing microtubule depolymerization, inhibiting mitosis. We did 
not determine whether the additive effect that we observed was down to sensitization to 
docetaxel, or the additive impact of iNOS overexpression and docetaxel treatment; MDA-
MB-231s treated with 100 nM docetaxel arrested in G2/M phase of the cell cycle  47, 
while treatment with ·NO donor DETA-NONOate arrested MDA-MB-231s in G1  48. 
There is precedent for ·NO sensitizing to chemotherapy. In MDA-MB-231, hypoxia-
induced resistance to doxorubicin and 5-HT was attenuated by treatment with 
nitroglycerin (a ·NO donor); low oxygen levels in conditions of hypoxia prohibit the 
biogenesis of ·NO, so these findings support a role for endogenous ·NO in 
chemosensitzation  49. CMV-iNOS treatment sensitized human cancer cells to cisplatin in 
vitro, and also RIF-1 murine xenografts to the same in vivo  9. In a C6 glioma model, 
overexpression of dimethylarginine dimethylaminohydrolase (DDAH) (which 
metabolizes asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor) 
sensitized C6 xenografts to docetaxel  50. Additionally, in lung adenocarcinoma patients, 
nitroglycerin patch treatment improved response to docetaxel/carboplatin therapy 51. It is 
likely that there is potential for RALA/iNOS therapy to similarly sensitize to docetaxel, 
and that optimization of the regimen is required to determine the best therapeutic window 
in vivo. It is also possible that iNOS gene therapy may be of more benefit in a model of 
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docetaxel resistance, which is more representative of those that have failed 
chemotherapy.  
 
Conclusions 
Our data demonstrate a clear anti-cancer effect of RALA/iNOS gene therapy for 
metastatic breast cancer. Overexpression of iNOS with concomitant increase in ·NO 
liberation is a strategy for direct cytotoxicity, and requires additional interrogation for its 
ability to sensitize to other cytotoxic approaches. Measurement of circulating nitrites was 
a method for confirmation of iNOS transgene activity, and could harnessed to determine 
iNOS therapeutic efficacy. The nucleic acid delivery ability of RALA is unquestionable; 
beyond utility as a reporter gene delivery vehicle 1, it effectively delivers siRNAs  2, and 
RALA/DNA nanoparticles were evaluated as components of a DNA vaccination device  
21. However, this is the first report validating systemically-delivered RALA/nucleic acid 
therapeutics. Further development of this potent RALA/iNOS treatment is required with 
respect to dosing, adjuvant therapies and increasing circulation times.  
 
 
Materials and methods 
 
Materials 
Unless otherwise stated, reagents used were from Sigma (Dorset, UK).  
 
Cell culture 
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ZR-75-1 breast cancer cells were purchased from ATCC, and maintained in RPMI-1640 
(Life Technologies) supplemented with 10% fetal bovine serum (PAA). MDA-MB-231-
luc-D3H1 were purchased from PerkinElmer Inc. (Buckinghamshire, UK) and 
maintained in DMEM (Life Technologies) supplemented with 10% fetal bovine serum 
(PAA). Cells were cultivated in 175 cm2 flasks in a humidified incubator; once 80-90% 
confluency was reached, cells were passed to maintain exponential growth. Mycoplasma 
absence was confirmed monthly, using Plasmotest (Invivogen, France).  
 
Plasmid DNA preparation 
MAX Efficiency® DH5α™ Competent Cells containing relevant plasmids (pEGFP-
N1/CMV-iNOS/hOC-iNOS) were cultured in a shaking incubator overnight at 37°C in 
Luria broth containing the appropriate antibiotic. Plasmid DNA was isolated and purified 
using PureLink® HiPure Plasmid Maxiprep Kits (Life Technologies, Paisley, UK), using 
the manufacturer’s protocol. Plasmid DNA was dissolved in ultrapure water, and stored 
at -20°C.  
 
Nanoparticle complexation and characterization 
RALA was custom synthesized using solid-state synthesis (FMOC) (Biomatik, USA) and 
supplied as a desalted lyophilized powder. Reconstitution was in ultrapure water to a 
stock concentration of 5.8 mg/ml. Aliquots were stored at -20°C until use.  
 
Plasmid DNA/RALA nanocomplexes were constructed as previously described  1. 
Briefly, plasmid DNA was incubated with RALA for 30 min at room temperature to 
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facilitate electrostatic interaction of the anionic DNA with the cationic peptide. 
Nanoparticles were complexed at N:P10 (N:P ratio is the molar ratio of positively 
charged nitrogen atoms in the peptide to negatively charged phosphates in the pDNA 
backbone – at N:P10, 14.5 µg of RALA is used to neutralize 1 µg of DNA). 
Nanoparticles were analyzed in terms of their hydrodynamic size and particle charge 
using a Nano ZS Zetasizer and DTS software (Malvern Instruments, UK).  
 
Intracellular nanoparticle tracking 
Plasmid DNA (pEGFP-1 – analogous to pEGFP-N1, but lacking the promoter) was 
labeled with Cy3 using a Mirus Bio LabelIt® kit (Cambridge Bioscience, Cambridge, 
UK) as recommended by the manufacturer. Cy3-labeled DNA was complexed with 
RALA as before, and the impact of the fluorophore on nanoparticle size and charge was 
determined as above.  
 
MDA-MB-231-luc-D3H1 were seeded in 24 well plates on round coverslips at 104 cells 
per coverslip, and allowed to adhere for 2 h; the wells were then supplemented with 
complete growth medium, and incubated overnight. Following 2 h starvation in Opti-
MEM (Life Technologies), nanoparticle complexes were added to the Opti-MEM, and 
cells were transfected for 30, 60 and 120 min. Cell actin cytoskeleton was stained using 
FITC-conjugated phalloidin (Life Technologies), and coverslips were mounted onto 
microscope slides using Diamond Antifade with DAPI (Life Technologies).  
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Nanoparticle subcellular localization was analyzed in MDA-MB-231-luc-D3H1 by 
confocal fluorescence microscopy using a Leica SP5 microscope and LAS-AF software.  
 
Clonogenic assay 
The impact of RALA/iNOS on clonogenicity of MDA-MB-231-luc-D3H1 was assessed. 
MDA-MB-231-luc-D3H1 were seeded in T25 culture flasks at a density of 106 cells per 
flask, and incubated overnight. Following a 2 h starvation in Opti-MEM, cells were 
transfected with RALA/CMV-iNOS or RALA/hOC-iNOS nanoparticle formulations, 
equivalent to 6 µg DNA per flask; transfection was for 6 h, following which, transfection 
media were replaced with normal growth medium, and cells returned to the incubator for 
overnight incubation. Following 24 h, cells were trypsinized, counted and plated in 
triplicate in 6 well plates at 500/1000 cells per well. Plates were incubated at 37°C for 12 
days, following which, colonies were fixed and stained using 0.4% crystal violet (Sigma) 
in 70% methanol; excess stain was removed by gentle washing in water, and once dry, 
colonies were manually counted. Treatment with 1 mM aminoguanidine (NOS inhibitor), 
where appropriate, began 24 h post plating into clonogenic plates.  
 
Vector neutralization assay 
Before commencing in vivo therapeutic assessment of RALA/iNOS nanoparticles, we 
determined whether repeated administration of nanoparticles induced vector 
neutralization in a competent immune system. Nanoparticles (comprising 10 µg pEGFP-
N1 complexed with RALA at N:P10) were formulated as above in a volume of 100 µl. 
Treatments were delivered via the tail vein of male C57BL/6 mice (6-8 weeks old at 
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beginning of experiment) using a 29G insulin syringe (Terumo). PBS, and DNA and 
RALA only treatments were also performed. Treatments were administered once, twice 
or thrice (for multiple administrations, one week elapsed between treatments). One week 
following final administration, mice were sacrificed by CO2 asphyxiation, blood was 
collected by cardiac puncture, serum was isolated, and sera from triplicate mice were 
pooled, heat inactivated and stored at -20°C.  
 
5x103 ZR-75-1 were seeded in triplicate wells of 96 well plates and allowed to adhere 
overnight. Cells were starved in Opti-MEM for 2 h prior to transfection. RALA/pEGFP-
N1 nanoparticles were prepared and incubated for 30 min in Opti-MEM containing sera 
(0, 0.1, 1 and 10% serum) from mice that had received the indicated treatment. 
Transfections were for 6 h, following which, Opti-MEM was replaced with RPMI-1640. 
48 h later, cells were analyzed for EGFP expression by fluorescence microscopy using a 
Nikon Eclipse TE300 fluorescence microscope, and by flow cytometry using a BD 
FACSCalibur.  
 
Neutralising Antibody Assay 
Sera neutralizing antibody content was analyzed by ELISA. 52 Maxisorp ELISA plates 
(Nunc) were coated overnight at 4°C with RALA/pEGFP-N1 nanoparticles in PBS. 
Wells were washed with PBS/0.05% Tween 20, and blocked with PBS/1% bovine serum 
albumin for 1 h at room temperature. The wells were probed (1 h, room temperature) 
with diluted sera (1:10, 1:100, 1:1000) from mice that had received PBS, pEGFP-N1, 
RALA, or RALA/pEGFP-N1 nanoparticles, washed thrice with PBS/0.05% Tween 20, 
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and probed with an anti-mouse IgA,M,G-HRP secondary antibody (AdB Serotec). 
Following three further washes, tetramethylbenzidine substrate was added, quenched 
with 1N HCl, and absorbance quantified at 450 nm, with background absorbance (550 
nm) subtracted.  
 
iNOS transgene expression 
MDA-MB-231-luc-D3H1 were plated (104 cells per well of a 24 well plate) and allowed 
to adhere overnight, and were transfected with RALA/CMV-iNOS or RALA/hOC-iNOS 
for 6 h, following which Opti-MEM was replaced with phenol red-free MEM/10% fetal 
bovine serum. 48 h later, MEM nitrite content was assayed using Greiss test for nitrites 
(Active Motif, Belgium) as instructed by the manufacturer. The cellular iNOS transgene 
expression was measured via western blot as previously described. 53  
 
iNOS-mediated docetaxel sensitization 
MDA-MB-231-luc-D3H1 were plated in 24 well plates at 105 cells per well and allowed 
to attach overnight. Cells were transfected with RALA/hOC-iNOS or RALA/CMV-iNOS 
nanoparticles (0.5 µg DNA/ well) for 6 h, following which, cells were returned to 
DMEM. 24 h following transfection, DMEM was replaced with DMEM containing 
docetaxel (0, 4, 20, 100, 500, 2500 ng/ml). Following a further 48 h incubation, 
docetaxel-containing DMEM was replaced with DMEM containing D-luciferin (Perkin 
Elmer) at 150 µg/mL; subsequent to a 2 min incubation, luminescence was determined 
using IVIS imaging. Luminescence in wells was quantified using Living Image software 
(Perkin Elmer).  
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Establishment of metastatic disease 
All animal experiments were carried out in accordance with the Animal (Scientific 
Procedures) Act 1986 and conformed to the current UKCCCR guidelines. Mice were 
bred in-house and maintained using the highest possible standard of care, and priority 
was given to their welfare.  
 
Mice (6-8 weeks old) were anesthetized using isoflurane (3% in O2) and restrained using 
surgical adhesive tape in a supine position. Thoracic fur was removed. Using a 1 ml 
syringe fitted with a 26G needle, mice were implanted with 100 µl of MDA-MB-231-luc-
D3H1 at 106 cells/ml via the left cardiac ventricle – the cell suspension was gently 
injected into the ventricle, following which the needle was held in place for 10 s to 
minimize leakage of delivered cells from the ventricle. To confirm appropriate delivery, 
mice were injected with 150 mg/kg D-luciferin i.p., and after 15 min incubation, 
isoflurane-anesthetized mice were imaged using an IVIS200 (Xenogen) imaging system. 
Appropriate left ventricular delivery was indicated by appearance of luminescence 
throughout the mouse, while inappropriate delivery was indicated by luminescence being 
limited to the thoracic cavity; such mice were sacrificed by CO2 asphyxiation. 
 
Gene therapy regimen 
Beginning 48 h post-implantation, mice received treatments twice weekly for five 
treatments. Treatments comprised RALA/CMV-iNOS or RALA/hOC-iNOS complexes 
(corresponding to 5x10 µg DNA per mouse) at N:P10, while vehicle control (RALA 
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equivalent to the mass of RALA used in the gene therapy regimens) and untreated 
controls were also performed. Treatment was via tail vein injection. A subgroup of mice 
received docetaxel treatment in addition to iNOS gene therapy; docetaxel treatment (5 
mg/kg i.p.) commenced seven days post-implantation, and was weekly for three weeks; 
gene therapy treatments were as before. 
 
Mice were monitored for micrometastases development using routine (twice weekly) 
IVIS imaging as described above, as well as body mass measurement. A loss of 20% 
original body mass was deemed sufficient to necessitate sacrifice of the mouse. The 
degree of whole body luminescence in mice was determined using Living Image software 
(Perkin Elmer). At regular intervals, blood samples were taken from mice following tail 
prick, and stored in EDTA-coated tubes. Blood nitrite levels were assayed using 
ArrowSTRAIGHT™ Nitric Oxide Measurement System (Lazar Labs).  
 
Statistics 
All statistics were performed using GraphPad Prism, version 6.0g for Mac OS X. The 
various tests used are described throughout.  
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Figure legends 
Figure 1 - Complexation of plasmid DNA with RALA produces nanoparticles 
suitable for cellular delivery. 
A, incubation of plasmid DNA with RALA resulted in nanoparticles that did not exceed 
100 nm in diameter, with a positive charge of approximately 20-25 mV. B, Cy3-labeled 
DNA forms nanoparticles with RALA that resemble those formed with unlabeled DNA. 
Datapoints represent mean ± SD; N ≥ 3. C, orthogonal sectioning of Z-stacks of MDA-
MB-231-luc-D3H1 transfected with RALA/Cy3-pEGFP-1. RALA is delivers plasmid 
DNA to the nucleus of MDA-MB-231-luc-D3H1 within 120 min. Green – actin 
cytoskeleton; blue – nucleus; red – Cy3.  
 
Figure 2 - Administration of RALA/pEGFP-N1 nanoparticles to immunocompetent 
mice does not provoke a neutralizing antibody response. 
A, flow cytometric analysis of GFP in ZR-75-1 after incubation of RALA/pEGFP-N1 
nanoparticles with sera from C57BL/6 mice that received the indicated treatment 
(PBS/DNA/RALA/NPs) weekly for up to 3 weeks. *p<0.05, **p<0.01, ***p<0.001 
compared to expression elicited by RALA/pEGFP-N1 nanoparticles (NP) that had been 
incubated in sera from mice that had received nanoparticles (multiple comparisons 
ANOVA). B, fluorescence micrographs of ZR-75-1 transfected with RALA/pEGFP-N1 
nanoparticles following incubation in FBS or serum from mice that received two 
administrations of RALA/pEGFP-N1. C, sera neutralizing antibody (immunoreactivity of 
an anti-mouse IgA, IgG and IgM) content analyzed by ELISA. Datapoints represent mean 
± SD; N ≥ 3. 
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Figure 3- Validation of hOC- and CMV-driven iNOS plasmids. 
A, iNOS protein expression in MDA-MB-231-luc-D3H1 48 h post-transfection with 
RALA/hOC-iNOS or RALA/CMV-iNOS (comprising 0.5 µg DNA) at N:P10 for 6 h; 
·NO generation was confirmed by Greiss test. B, MDA-MB-231-luc-D3H1 
overexpressing iNOS form fewer clonogenic colonies, which is partially inhibited by 1 
mM aminoguanidine. Datapoints represent mean ± SD; N = 3. 
 
Figure 4 - Treatment with RALA/hOC-iNOS or RALA/CMV-iNOS improves 
survival of MDA-MB-231-luc-D3H1 metastases-bearing mice. 
A, IVIS images of mice (control and RALA/iNOS) at indicated timepoints post-
implantation. B, survival of metastases-bearing mice (N=6 (control, RALA) or ≥ 9 (either 
RALA/iNOS strategy)). C, weight loss of exemplar mice. D, total bioluminescence in 
exemplar mice; inverted triangles denote treatment timepoints. E, relative blood nitrite 
levels in control, RALA/hOC-iNOS and RALA/CMV-iNOS treated mice.  
  
Figure 5 - Assessment of iNOS overexpression on sensitization of MDA-MB-231-luc-
D3H1 to docetaxel. 
A, transfection of MDA-MB-231-luc-D3H1 with RALA/hOC-iNOS or RALA/CMV-
iNOS increases the potency of docetaxel in vitro. B, RALA/hOC-iNOS or RALA/CMV-
iNOS treatment produces a slight additive improvement in response to docetaxel in 
MDA-MB-231-luc-D3H1 metastases-bearing mice. N≥5. C and D, weight loss and 
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bioluminescence accumulation data for exemplar mice; closed inverted triangles denote 
gene therapy treatment, open inverted triangles denote docetaxel treatment.  
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